检索范围:
排序: 展示方式:
《医学前沿(英文)》 2022年 第16卷 第4期 页码 610-617 doi: 10.1007/s11684-021-0827-8
关键词: bevacizumab elderly patient advanced non-small-cell lung cancer overall survival toxicity
null
《医学前沿(英文)》 2013年 第7卷 第2期 页码 157-171 doi: 10.1007/s11684-013-0272-4
Non-small-cell lung cancer (NSCLC) is the most common cause of premature death among the malignant diseases worldwide. The current staging criteria do not fully capture the complexity of this disease. Molecular biology techniques, particularly gene expression microarrays, proteomics, and next-generation sequencing, have recently been developed to facilitate effectively its molecular classification. The underlying etiology, pathogenesis, therapeutics, and prognosis of NSCLC based on an improved molecular classification scheme may promote individualized treatment and improve clinical outcomes. This review focuses on the molecular classification of NSCLC based on gene expression microarray technology reported during the past decade, as well as their applications for improving the diagnosis, staging and treatment of NSCLC, including the discovery of prognostic markers or potential therapeutic targets. We highlight some of the recent studies that may refine the identification of NSCLC subtypes using novel techniques such as epigenetics, proteomics, or deep sequencing.
关键词: non-small-cell lung cancer molecular typing individualized medicine molecular-targeted therapy gene expression profiling
Jiahui Xu, Qianqian Wang, Elaine Lai Han Leung, Ying Li, Xingxing Fan, Qibiao Wu, Xiaojun Yao, Liang Liu
《医学前沿(英文)》 2020年 第14卷 第1期 页码 60-67 doi: 10.1007/s11684-019-0694-8
关键词: BPTF small molecule epigenetics non-small-cell lung cancer
Fen LAN, Shengdao XIONG, Weining XIONG, Guopeng XU, Xiaoxia LU
《医学前沿(英文)》 2009年 第3卷 第1期 页码 41-44 doi: 10.1007/s11684-009-0009-6
关键词: Syk kinase carcinoma non-small-cell lung tumor suppressor protein p53
《医学前沿(英文)》 2023年 第17卷 第1期 页码 18-42 doi: 10.1007/s11684-022-0976-4
关键词: non-small cell lung cancer driver mutations treatment strategy resistant mechanism immune-checkpoint inhibitors
null
《医学前沿(英文)》 2011年 第5卷 第1期 页码 53-60 doi: 10.1007/s11684-011-0121-2
Video-assisted thoracoscopic surgery (VATS) provides a new approach for treating early-stage lung cancer. Lobectomy by VATS has many advantages over conventional thoracotomy, such as shorter recovery time, less postoperative pain, and faster resumption of a normal lifestyle. However, there is still much debate on the role of VATS in lobectomy for the treatment of lung cancer. Concerns regarding safety, the extent of mediastinal lymph node dissection, and long-term survival have made some surgeons apprehensive of its validity for lung cancer. In this paper, we review the development of thoracoscopy, the present status of VATS for early stage of non-small cell lung cancer (NSCLC), and comparison between VATS and open thoracotomy in the management of NSCLC.
关键词: non-small cell lung cancer video-assisted thoracoscopic surgery lobectomy
Molecular markers and pathogenically targeted therapy in non-small cell lung cancer
Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD
《医学前沿(英文)》 2009年 第3卷 第3期 页码 245-255 doi: 10.1007/s11684-009-0044-3
关键词: lung cancer carcinoma non-small cell lung cancer molecular markers targeted therapy
CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer
《医学前沿(英文)》 2023年 第17卷 第1期 页码 105-118 doi: 10.1007/s11684-022-0934-1
关键词: osimertinib anti-CD47 antibody combination strategy ADCP EGFR
null
《医学前沿(英文)》 2013年 第7卷 第4期 页码 462-476 doi: 10.1007/s11684-013-0270-6
Evaluating the effects of novel drugs on appropriate tumor models has become crucial for developing more effective therapies that target highly tumorigenic and drug-resistant cancer stem cell (CSC) populations. In this study, we demonstrate that a subset of cancer cells with CSC properties may be enriched into tumor spheroids under stem cell conditions from a non-small cell lung cancer cell line. Treating these CSC-like cells with gemcitabine alone and a combination of gemcitabine and the novel CHK1 inhibitor PF-00477736 revealed that PF-00477736 enhances the anti-proliferative effect of gemcitabine against both the parental and the CSC-like cell populations. However, the CSC-like cells exhibited resistance to gemcitabine-induced apoptosis. Collectively, the spheroid-forming CSC-like cells may serve as a model system for understanding the mechanism underlying the drug resistance of CSCs and for guiding the development of better therapies that can inhibit tumor growth and eradicate CSCs.
关键词: drug resistance cancer stem cell checkpoint kinase 1 (CHK1) PF-00477736 lung cancer tumorigenicity
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup
《医学前沿(英文)》 2022年 第16卷 第5期 页码 766-772 doi: 10.1007/s11684-021-0916-8
关键词: anlotinib chemotherapy short-term relapsed small-cell lung cancer
YANG Kunyu, LIU Li, ZHANG Tao, WU Gang, CAO Fengjun, WANG Jianhua
《医学前沿(英文)》 2007年 第1卷 第4期 页码 381-385 doi: 10.1007/s11684-007-0074-7
关键词: significant difference irradiation unresectable non-small-cell induction chemotherapy influence
Fine-tuning cell organelle dynamics during mitosis by small GTPases
《医学前沿(英文)》 2022年 第16卷 第3期 页码 339-357 doi: 10.1007/s11684-022-0926-1
Discovery of small molecule degraders for modulating cell cycle
《医学前沿(英文)》 页码 823-854 doi: 10.1007/s11684-023-1027-5
null
《医学前沿(英文)》 2018年 第12卷 第2期 页码 224-228 doi: 10.1007/s11684-017-0538-3
Bronchiolitis obliterans syndrome (BOS) after hematopoietic stem cell transplantation (HSCT) is a major cause of morbidity and mortality with limited treatment options. Lung transplantation (LTX) has been rarely reported as a treatment option for selected HSCT recipients with this problem. In the present study, we reported six patients who underwent LTX due to BOS after HSCT (two females, four males) from January 2012 to December 2014 in our center. The median time from HSCT to diagnosis of BOS was 2.5 years (ranging from 1 to 5 years). At a median time of 4 years (ranging from 2 to 5 years) after diagnosis of BOS, four patients received bilateral sequential LTX, and two patients received single LTX. One of the recipients suffered from mild acute rejection after LTX, another suffered from primary lung graft dysfunction on post-operation day 2, and three experienced fungal infections. The median time for follow-up after LTX was 19.5 months (ranging from 12 to 39 months). At present, all patients are alive with good functional capacity and no relapse of BOS and hematologic malignancy conditions. Patients who received bilateral LTX have better pulmonary functions than patients who received single LTX.
关键词: bronchiolitis obliterans syndrome (BOS) hematopoietic stem cell transplantation (HSCT) lung transplantation (LTX)
Orlistat induces ferroptosis-like cell death of lung cancer cells
《医学前沿(英文)》 2021年 第15卷 第6期 页码 922-932 doi: 10.1007/s11684-020-0804-7
标题 作者 时间 类型 操作
Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamousnon-small-cell lung cancer: a retrospective analysis
期刊论文
Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis
null
期刊论文
Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-celllung cancer
Jiahui Xu, Qianqian Wang, Elaine Lai Han Leung, Ying Li, Xingxing Fan, Qibiao Wu, Xiaojun Yao, Liang Liu
期刊论文
Expression of Syk in non-small cell lung cancer and its relationship with clinicopathological parameters
Fen LAN, Shengdao XIONG, Weining XIONG, Guopeng XU, Xiaoxia LU
期刊论文
Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future
期刊论文
Lobectomy by video-assisted thoracoscopic surgery (VATS) for early stage of non-small cell lung cancer
null
期刊论文
Molecular markers and pathogenically targeted therapy in non-small cell lung cancer
Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD
期刊论文
Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-likecells enriched with tumor spheroids from a non-small cell lung cancer cell line
null
期刊论文
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup
期刊论文
Improved local control without elective nodal radiotherapy in patients with unresectable NSCLC treated by 3D-CRT
YANG Kunyu, LIU Li, ZHANG Tao, WU Gang, CAO Fengjun, WANG Jianhua
期刊论文
Lung transplantation for bronchiolitis obliterans syndrome after allogenic hematopoietic stem cell transplantation
null
期刊论文